Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer

Key Appointment in the Advancement of SJX-653 as a Novel and Selective NK3 Antagonist in Clinical Development as a Once-Daily Non-Hormonal Treatment for Menopausal Vasomotor Symptoms, or "Hot Flashes" WALTHAM, Mass., Feb. 4, 2019 -- (Healthcar... Biopharmaceuticals, Personnel Sojournix, Hot Flashes, menopause
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news